The scale and speed of the successful turnaround at Santhera Pharmaceuticals has gone largely unnoticed by the investment community but a restructuring and a very promising Duchenne muscular dystrophy (DMD) project suggest that the Swiss biotech's comeback is nearly complete.
Santhera's Transformation Should Turn Investors' Heads
DMD Drug To Be Filed With FDA Imminently
The Swiss biotech had a tough time after the failure of idebenone for Duchenne muscular dystrophy, but CEO Dario Eklund tells Scrip that with a new soon-to-be submitted compound, vamorolone, it has an effective and much safer alternative to steroids for the treatment of the progressive muscle degeneration genetic disorder.
More from Rare Diseases
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.